GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Buyback Yield %

CERO (CERo Therapeutics Holdings) Buyback Yield % : 0.00 (As of Apr. 10, 2025)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

CERo Therapeutics Holdings's current buyback yield was 0.00%.


CERo Therapeutics Holdings Buyback Yield % Historical Data

The historical data trend for CERo Therapeutics Holdings's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Buyback Yield % Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
Buyback Yield %
- -

CERo Therapeutics Holdings Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of CERo Therapeutics Holdings's Buyback Yield %

For the Biotechnology subindustry, CERo Therapeutics Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CERo Therapeutics Holdings's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's Buyback Yield % falls into.


;
;

CERo Therapeutics Holdings Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

CERo Therapeutics Holdings's Buyback Yield for the fiscal year that ended in Dec. 2022 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 0
=N/A%

CERo Therapeutics Holdings's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 13.76175
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


CERo Therapeutics Holdings Buyback Yield % Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings Business Description

Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, South San Francisco, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.